Context Therapeutics Inc. (CNTX)
Market Cap | 29.54M |
Revenue (ttm) | n/a |
Net Income (ttm) | -23.96M |
Shares Out | 15.97M |
EPS (ttm) | -1.50 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,184,893 |
Open | 1.700 |
Previous Close | 1.750 |
Day's Range | 1.660 - 1.880 |
52-Week Range | 0.470 - 1.880 |
Beta | 2.17 |
Analysts | Strong Buy |
Price Target | 4.00 (+128.57%) |
Earnings Date | May 17, 2024 |
About CNTX
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelph... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for CNTX stock is "Strong Buy." The 12-month stock price forecast is $4.0, which is an increase of 128.57% from the latest price.
News
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in mid-2024 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) -- Context ...
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
Important Regulatory Milestone Supports Next Phase of CTIM-76 Development Important Regulatory Milestone Supports Next Phase of CTIM-76 Development
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash and cash equivalents will continue to fund operations into l...
Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
CTIM-76 IND filing on track for late Q1 2024 Cash and cash equivalents of $21.7 million as of September 30, 2023 Company expects its cash and cash equivalents will continue to fund operations into lat...
Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting
PHILADELPHIA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announce...
Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results
Company expects its cash and cash equivalents will continue to fund operations into late 2024 Cash and cash equivalents of $25.1 million as of June 30, 2023 CTIM-76 IND filing on track for Q1 2024 PHI...
Context Therapeutics to Participate in Two August 2023 Investor Conferences
PHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company dedicated to improving the lives of patients living w...
Context Therapeutics Reports First Quarter 2023 Operating and Financial Results
CTIM-76 IND filing on track for Q1 2024 Preclinical data on CLDN6 bispecific antibody CTIM-76 presented at AACR Annual Meeting 2023 Cash and cash equivalents of $29.8 million as of March 31, 2023 PHIL...
Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference
PHILADELPHIA, PA / ACCESSWIRE / April 18, 2023 / Context Therapeutics Inc. (NASDAQ:CNTX) is a biopharmaceutical company committed to advancing medicines for solid tumors by harnessing novel and innova...
Context Therapeutics to Participate in Two April 2023 Investor Conferences
PHILADELPHIA, April 03, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company developing novel treatments for solid tumors, today ...
Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
Company prioritizing pipeline to focus on CTIM-76 development and discontinuing ONA-XR program
Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
Context to host webinar with AACR presenter on Monday, April 17, 2023, at 4:30 p.m. ET Context to host webinar with AACR presenter on Monday, April 17, 2023, at 4:30 p.m. ET
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
ONA-XR initial data signals positive clinical activity and confirmed tumor shrinkage
Context Therapeutics' Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
First endocrine innovation in more than 20 years which has shown improved efficacy over standard-of-care treatments in patients with advanced breast cancer
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
Lonza to support the development and manufacturing of CTIM-76, Context's CLDN6 x CD3 bispecific antibody clinical candidate
Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones
CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody clinical candidate
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
Data presented at San Antonio Breast Cancer Symposium ® demonstrate preliminary 4-month PFS rate of 44% in ongoing Phase 2 trial in second- or third-line metastatic breast cancer
Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
CTIM-76 named as lead candidate to target Claudin 6 positive cancers
Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium
Company reports initial ONA-XR data from the ongoing Phase 2 SMILE trial for metastatic breast cancer will be presented Company reports initial ONA-XR data from the ongoing Phase 2 SMILE trial for met...
Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results
Company reports preliminary ONA-XR data from two ongoing Phase 2 trials
Context Therapeutics to Participate in the ThinkEquity Conference
Philadelphia, Pennsylvania--(Newsfile Corp. - October 20, 2022) - Context Therapeutics Inc. (NASDAQ: CNTX) ("Context" or the "Company"), a women's oncology company developing novel treatments for brea...
Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024
Company to focus resources on advancing ONA-XR ELONA Phase 1b/2 clinical trial and on advancing CLDN6xCD3 bispecific antibody toward IND Company to focus resources on advancing ONA-XR ELONA Phase 1b/2...
Context Therapeutics® to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
PHILADELPHIA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women's oncology company developing novel treatments for breast and gynecologi...
Context Therapeutics® Reports Second Quarter 2022 Operating and Financial Results
Announced new clinical trial collaboration with Menarini Group to evaluate ONA-XR plus elacestrant in metastatic breast cancer
Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination
Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models Context to initiate Phase 1b/2 clinical trial in Q4 2022 PHILADELPHIA and FLOREN...